Medical Devices

Request for TOC Request for Sample
BUY NOW

North America Transfection Reagent and Equipment Market – Industry Trends and Forecast to 2030

Medical Devices | Published Report | Mar 2023 | North America | 350 Pages | No of Tables: 45 | No of Figures: 57

Report Description

North America Transfection Reagent and Equipment Market, By Products (Reagent & Kits and Instruments), Stage (Research, Preclinical, Clinical Phases, and Commercial), Type (Transient Transfection Reagent and Equipment, Stable Transfection Reagent, and Equipment), Methods (Non-viral Methods and Viral Methods), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), and Others), Organism (Mammalian Cells, Plants, Fungi, Virus, and Bacteria), Application (In Vitro Application, In Vivo Application, Bioproduction and Others), End User (Biopharma, CROs, (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Industry Trends and Forecast to 2030


North America Transfection Reagent and Equipment Market Analysis and Insights

Transfection involves nucleic acid introduction in eukaryotic cells by viral and non-viral methods. The transfection method can overcome the challenge of transferring the negatively charged membrane. Chemicals such as calcium phosphate and diethylaminoethyl (DEAE) ‐dextran or cationic lipid-based Reagent react with the outer DNA coat. It neutralizes the overall negative charge, imparts the positive amount to the molecule, and hence allows DNA delivery. Physical methods such as electroporation create minute pores in the cell membrane by applying electric voltage, allowing entry of DNA directly into the cytoplasm. DEAE-dextran is used for transient transfection; however, lipofection can achieve stable transfection and hence can be used for long-term protein expression. Calcium phosphate-mediated transfection can also be used for stable transfection. The viral transfection method achieves high efficiency and is used for several phases of pharmaceutical product development.



The transfection method is used for several applications involving agriculture for crop protection and enhancing yield, for the production of synthetic biology products to enhance flavors and fragrances, and for enhancing single-cell protein, among others. The demand for transfection has increased in both developed and developing countries, and the reason behind this is the increasing occurrence of chronic diseases. The transfection market is growing due to the growing demand for chimeric genes and the utilization of biopharmaceuticals in the production of proteins. The market will grow in the forecast period due to the exploration of emerging markets, strategic initiatives by market players, and increasing government support.

The high cost of instruments, selective effectiveness of transfection reagent and cell damage induced by the transfection methods are expected to restrain the North America transfection reagent and equipment market growth.

The market is growing due to several strategic initiatives adopted by market players involving acquisition, collaboration, and partnership.

Data Bridge Market Research analyzes that the North America transfection reagent and equipment market is expected to reach the value of USD 1,319,255.58 thousand by 2030, at a CAGR of 9.9% during the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020-2016)

Quantitative Units

Revenue in Thousand, Volumes in Units, Pricing in USD

Segments Covered

By Products (Reagent & Kits and Instruments), Stage (Research, Preclinical, Clinical Phases, and Commercial), Type (Transient Transfection Reagent and Equipment, Stable Transfection Reagent, and Equipment), Methods (Non-viral Methods and Viral Methods), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), and Others), Organism (Mammalian Cells, Plants, Fungi, Virus, and Bacteria), Application (In Vitro Application, In Vivo Application, Bioproduction and Others), End User (Biopharma, CROs, (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others).

Countries Covered

U.S., Canada, and Mexico.

Market Players Covered

Some of the major players operating in this market are Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation), Avanti Polar Lipids (A Subsidiary of  Croda International Plc),  PerkinElmer chemagen Technologie GmbH (A Subsidiary of  PerkinElmer Inc.), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (A Subsidiary of F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (A Subsidiary of Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc., and Twist Bioscience, among others.

Market Definition

The transfection method is used to introduce RNA, DNA or protein products in cells to alter the phenotype and genotype of the organism. The transfection method involves the new gene transfer or transferring a gene construct such as Clustered regularly interspaced short palindromic repeats (CRISPR) for genome editing purposes. Transfection has wide applications in th  e field of immunotherapy, gene therapy, and cell therapy, among others. Transfection involves both non-viral and viral-mediated transfection. The chemical and physical methods can achieve non–viral transfection. The most common chemical method used for transfection is calcium phosphate transfection, and liposome transfection, among others. Viral transfection yields high transfection efficiencies, and various types of physical methods employed for transfection include microinjection, biolistic particle delivery, and electroporation, among which electroporation provides high transfection efficiency. Transfection is of two types either it can be transient or stable transfection. For short-term gene expression studies such as gene knock-out studies, small-scale production transient transfection method is preferred; however, long-term research studies and large-scale protein production stable transfection methods are widely adopted.

North America Transfection Reagent and Equipment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • RISE IN THE PREVALENCE OF CHRONIC DISEASES

The prevalence of chronic diseases is increasing worldwide, leading to the demand for effective and accurate treatment. Transfection is used to deliver targeted modified genes to treat several genetic diseases. The transfection method is also used for the delivery of the CRISPR gene, which can enhance adaptive immunity and prevent an individual from different diseases.

The increasing cases of chronic diseases such as COVID-19 and other infectious diseases have led to the discovery of effective gene therapy products which can replace the defective gene with the correct gene. The transfection method is widely used for gene therapy, among others. As the demand for effective and accurate treatment is increasing worldwide, the demand for gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy to have the potential for chronic disease treatment are also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is acting as a driver for the North America transfection Reagent and equipment market growth.

  • DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

Synthetic biology is a new era of biology that incorporates the engineering principle into biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand for synthetic biology products is increasing worldwide, the use of transfection products is also increasing.

The demand for synthetic biology products is increasing due to the increasing demand for effective and innovative products. The manufacturing of synthetic products enhances the demand for transfection products, as gene transfer can be accompanied by the transfection method, among others. Thus, this signifies that synthetic product development drives the North America transfection Reagent and equipment market growth.

Restraint

  • CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

Some transfection methods have been reported to cause cell damage, reducing the reproducibility of the overall method. Among the several kinds of transfection procedures, electroporation has been reported to cause maximum cell damage as per the increase in voltage. This cell damage lowers the efficiency rate and impacts the ongoing project.

One of the most common side effects of the transfection procedure is cell damage which lowers the cells metabolic events and leads to cell death. This damaged cell can enhance the media toxicity and hence produces inappropriate results. Thus, this suggests that cell damage induced by the transfection procedure acts as a restraint for the North America transfection Reagent and equipment market growth.

Opportunity

  • EXPLORATION OF EMERGING MARKET

The transfection products have been shown as promising tools for the genetic engineering and proteomic industry. The top market for transfection products is in Europe and North America. By looking at the positive outcomes of these products, many market players are penetrating their roots in growing economies involving China and India, among others. The emerging market allows these market players to combat the loss that arises from the well-established market.

As emerging markets allow the market players to overcome the economic downturn specified to particular established markets, investment and exploration of emerging markets allow the market players to engage in the development and manufacturing of transfection products to attain lucrative growth. Thus, this signifies that exploring emerging markets is an opportunity to grow the North America transfection Reagent and equipment market.

Challenge

  • LONG APPROVAL PROCEDURE

The long approval procedure for transfection reagents and instruments is a hindering agent for the growth of the transfection market. Transfection products are subjected to extensive regulations and have to monitor every time. The transfection products are widely used for the insertion of desired gene molecules in a particular cell line to obtain proteins and other biological compounds. This process is thus investigated and approved by the long and strict regulatory procedures. The long process required to get a positive result from every conducted clinical trial led to more time consumption and the investment of lots of money by market players.

The transfection Reagent are mostly subjected to 21CFR parts 210 and 211 U.S. FDA guidelines, according to which the manufacturers had to assure that the reagent manufactured meets the safety, packaging and processing characteristics proposed by the regulatory agencies. The owner or manufacturer has to submit licenses under section 351 of the PHS (Public Health Services) Act, which is quite a tedious procedure. Thus, this signifies that long approval procedures challenge the North America transfection Reagent and equipment market growth.

Recent Developments

  • In August 2021, Mirus Bio expanded the TransIT VirusGen platform for Good Manufacturing Practice (GMP) viral vector production to support cell and gene therapy development, process operations, and commercial production. The extension, referred to as TransIT VirusGen GMP Transfection Reagent, is designed to improve the packaging and delivery of vector DNA to suspension and adherent HEK 293 cell types to improve the production of recombinant adeno-associated viruses and lentiviral vectors.
  • In April 2021, BOC Sciences announced the launch of two in vivo RNA transfection kits, namely siRNA in vivo transfection kits and mRNA in vivo transfection kits, suitable for in vivo transfection of siRNA and mRNA, respectively.

North America Transfection Reagent and Equipment Market Scope

North America transfection Reagent and equipment market is segmented into nine notable segments such as products, stage, methods, type, types of molecule, application, end user, organism, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

PRODUCTS

  • INSTRUMENTS
  • REAGENT & KITS

On the basis of products, the North America transfection reagent and equipment market is segmented into instruments and reagent & kits.

STAGE

  • RESEARCH
  • PRECLINICAL
  • CLINICAL PHASES
  • COMMERCIAL

On the basis of stage, the North America transfection reagent and equipment market is segmented into research, preclinical, clinical phases and commercial.

TYPE

  • TRANSIENT TRANSFECTION REAGENT AND EQUIPMENT
  • STABLE TRANSFECTION REAGENT AND EQUIPMENT

On the basis of type, the North America transfection reagent and equipment market is segmented into transient transfection reagent and equipment and stable transfection reagent and equipment.

METHODS

  • NON-VIRAL METHODS
  • VIRAL METHODS

On the basis of methods, the North America transfection reagent and equipment market is segmented into non-viral methods and viral methods.

TYPES OF MOLECULE

  • PLASMID DNA
  • DNA OLIGONUCLEOTIDES
  • SMALL INTERFERING RNA (SIRNA)
  • PROTEINS
  • RIBONUCLEOPROTEIN COMPLEXES (RNPS)
  • OTHERS

On the basis of types of molecule, the North America transfection reagent and equipment market is segmented into plasmid DNA, DNA oligonucleotides, small interfering RNA (siRNA), proteins, ribonucleoprotein complexes (RNPs) and others.

ORGANISM

  • BACTERIA
  • MAMMALIAN CELLS
  • FUNGI
  • PLANTS
  • VIRUS

On the basis of organism, the North America transfection reagent and equipment market is segmented into bacteria, mammalian cells, fungi, plants and virus.

APPLICATION

  • BY TYPE

    • IN VITRO APPLICATION
    • IN VIVO APPLICATION
    • BIOPRODUCTION
    • OTHERS

  • BY INDUSTRY

    • AGRICULTURE
    • SYNTHETIC BIOLOGY
    • OTHERS

On the basis of application, the North America transfection reagent and equipment market is segmented by type into in vitro application, in vivo application, bioproduction, others and by industry into agriculture, synthetic biology, others.

END USER

  • BIOPHARMA
  • CROS
  • CMOS/CDMOS
  • ACADEMIA
  • HOSPITALS
  • CLINICAL LABS
  • OTHERS

On the basis of end user, the North America transfection reagent and equipment market is segmented into biopharma, CROs, CMOs/ CDMOs, academia, hospitals, clinical labs and others.

DISTRIBUTION CHANNEL

  • DIRECT TENDER
  • RETAIL SALES
  • OTHERS

On the basis of distribution channel, the North America transfection Reagent and equipment market is segmented into direct tender, retail sales and others.

North America Transfection Reagent and Equipment Market Regional Analysis/Insights

The North America transfection reagent and equipment market is categorized into many notable segments such as geography, products, stages, methods, type, types of molecule, application, end user, organism, and distribution channel.

The countries covered in this market report are U.S., Canada, and Mexico.

In 2023, North America is dominating due to the presence of key market players in the largest consumer market with high GDP. U.S is expected to grow due to rise in the prevalence of chronic and rare diseases leading to increase in the use of transfection reagent and equipment.

North America is dominating the market due to the increasing investment in healthcare is expected to boost the market growth. The U.S. dominates North America region due to strong presence of key players.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Transfection Reagent and Equipment Market Share Analysis

North America transfection reagent and equipment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the North America transfection reagent and equipment market.

Some of the major players operating in this market are Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation), Avanti Polar Lipids (A Subsidiary of  Croda International Plc),  PerkinElmer chemagen Technologie GmbH (A Subsidiary of  PerkinElmer Inc.), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (A Subsidiary of F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (A Subsidiary of Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc., and Twist Bioscience, among others.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS:

6 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, REGULATIONS

6.1 EUROPEAN UNION REGULATORY SCENARIO

6.2 U.S. REGULATORY SCENARIO

6.3 JAPAN REGULATORY SCENARIO

6.4 CHINA REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES

7.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

7.1.3 GROWING DEMAND FOR CHIMERIC GENES

7.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH

7.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS

7.2 RESTRAINTS

7.2.1 HIGH COST OF TRANSFECTION PRODUCTS

7.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS

7.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

7.3 OPPORTUNITIES

7.3.1 EXPLORATION OF EMERGING MARKET

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 SURGING LEVEL OF INVESTMENT

7.4 CHALLENGES

7.4.1 LONG APPROVAL PROCEDURE

7.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS-ASSOCIATED TRANSFECTION

7.4.3 LACK OF TRAINED PROFESSIONALS

8 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS

8.1 OVERVIEW

8.2 REAGENTS & KITS

8.3 INSTRUMENTS

9 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE

9.1 OVERVIEW

9.2 RESEARCH

9.3 PRECLINICAL

9.4 CLINICAL PHASES

9.5 COMMERCIAL

10 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT

10.3 STABLE TRANSECTION REAGENTS AND EQUIPMENT

11 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY METHODS

11.1 OVERVIEW

11.2 NON-VIRAL METHODS

11.3 VIRAL METHODS

12 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE

12.1 OVERVIEW

12.2 PLASMID DNA

12.3 SMALL INTERFERING RNA (SIRNA)

12.4 PROTEINS

12.5 DNA OLIGONUCLEOTIDES

12.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)

12.7 OTHERS

13 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM

13.1 OVERVIEW

13.2 MAMMALIAN CELLS

13.3 PLANTS

13.4 FUNGI

13.5 VIRUS

13.6 BACTERIA

14 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY APPLICATION

14.1 OVERVIEW

14.2 IN VITRO APPLICATION

14.2.1 IN VIVO APPLICATION

14.2.2 BIOPRODUCTION

14.2.3 OTHERS

14.2.4 SYNTHETIC BIOLOGY

14.2.5 AGRICULTURE

14.2.6 OTHERS

15 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 BIOPHARMA

15.3 CROS

15.4 CMOS/CDMOS

15.5 ACADEMIA

15.6 HOSPITALS

15.7 CLINICAL LABS

15.8 OTHERS

16 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

16.4 OTHERS

17 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION

17.1 NORTH AMERICA

17.1.1 U.S.

17.1.2 CANADA

17.1.3 MEXICO

18 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 THERMO FISHER SCIENTIFIC INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 PROMEGA CORPORATION

20.3.1 COMPANY SNAPSHOT

20.3.2 COMPANY SHARE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENT

20.4 TAKARA BIO INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 BIO-RAD LABORATORIES, INC.

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANANLYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 ALTOGEN BIOSYSTEMS

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.7 APPLIED BIOLOGICAL MATERIALS INC. (ABM)

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.1 CYTIVA

20.10.1 COMPANY SNAPSHOT

20.10.2 PRODUCT PORTFOLIO

20.10.3 RECENT DEVELOPMENT

20.11 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANANLYSIS

20.11.3 PRODUCT PORTFOLIO

20.11.4 RECENT DEVELOPMENT

20.12 GENLANTIS INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 GENO TECHNOLOGY INC., USA

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.14 GINKGO BIOWORKS

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENTS

20.15 LONZA

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANANLYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENT

20.16 MAXCYTE, INC.

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 MERCK KGAA

20.17.1 COMPANY SNAPSHOT

20.17.2 REVENUE ANALYSIS

20.17.3 PRODUCT PORTFOLIO

20.17.4 RECENT DEVELOPMENT

20.18 MIRUS BIO LLC.

20.18.1 COMPANY SNAPSHOT

20.18.2 PRODUCT PORTFOLIO

20.18.3 RECENT DEVELOPMENT

20.19 ORIGENE TECHNOLOGIES, INC.

20.19.1 COMPANY SNAPSHOT

20.19.2 PRODUCT PORTFOLIO

20.19.3 RECENT DEVELOPMENT

20.2 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)

20.20.1 COMPANY SNAPSHOT

20.20.2 REVENUE ANALYSIS

20.20.3 PRODUCT PORTFOLIO

20.20.4 RECENT DEVELOPMENT

20.21 POLYPLUS TRANSFECTION

20.21.1 COMPANY SNAPSHOT

20.21.2 PRODUCT PORTFOLIO

20.21.3 RECENT DEVELOPMENT

20.22 R&D SYSTEMS, INC.

20.22.1 COMPANY SNAPSHOT

20.22.2 PRODUCT PORTFOLIO

20.22.3 RECENT DEVELOPMENT

20.23 SBS GENETECH

20.23.1 COMPANY SNAPSHOT

20.23.2 PRODUCT PORTFOLIO

20.23.3 RECENT DEVELOPMENT

20.24 SIGNAGEN LABORATORIES

20.24.1 COMPANY SNAPSHOT

20.24.2 PRODUCT PORTFOLIO

20.24.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 2 NORTH AMERICA REAGENT AND KITS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 NORTH AMERICA INSTRUMENTS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE, 2021-2030 (USD THOUSAND)

TABLE 5 NORTH AMERICA RESEARCH IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 NORTH AMERICA PRECLINICAL IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 7 NORTH AMERICA CLINICAL PHASES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 NORTH AMERICA COMMERCIAL IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 9 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 NORTH AMERICA TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 NORTH AMERICA STABLE TRANSFECTION REAGENTS AND EQUIPMENT IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 12 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, BY METHODS, 2021-2030 (USD THOUSAND)

TABLE 13 NORTH AMERICA NON-VIRAL METHODS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 14 NORTH AMERICA VIRAL METHODS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 15 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE, 2021-2030 (USD THOUSAND)

TABLE 16 NORTH AMERICA PLASMID DNA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 NORTH AMERICA SMALL INTERFERING RNA (SIRNA) IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 NORTH AMERICA PROTEINS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 19 NORTH AMERICA DNA OLIGONUCLEOTIDES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 NORTH AMERICA RIBONUCLEOPROTEIN COMPLEXES (RNPS) IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM, 2021-2030 (USD THOUSAND)

TABLE 23 NORTH AMERICA MAMMALIAN CELLS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 NORTH AMERICA PLANTS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 NORTH AMERICA FUNGI IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 NORTH AMERICA VIRUS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 27 NORTH AMERICA BACTERIA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET , BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 29 NORTH AMERICA IN VITRO APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 NORTH AMERICA IN VIVO APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 NORTH AMERICA BIOPRODUCTION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 NORTH AMERICA APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY INDUSTRY, 2021-2030 (USD THOUSAND)

TABLE 34 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 35 NORTH AMERICA BIOPHARMA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 NORTH AMERICA CROS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 37 NORTH AMERICA CMOS/CDMOS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 NORTH AMERICA ACADEMIA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 NORTH AMERICA HOSPITALS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 NORTH AMERICA CLINICAL LABS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 43 NORTH AMERICA DIRECT TENDER IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 44 NORTH AMERICA RETAIL SALES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 NORTH AMERICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

List of Figure

FIGURE 1 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 10 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2030

FIGURE 13 THE TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN 2022 & 2030

FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET

FIGURE 16 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023

FIGURE 17 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023-2030 (USD THOUSAND)

FIGURE 18 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, CAGR (2023-2030)

FIGURE 19 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 20 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023

FIGURE 21 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023-2030 (USD THOUSAND)

FIGURE 22 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 23 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, LIFELINE CURVE

FIGURE 24 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023

FIGURE 25 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 26 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 27 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2022

FIGURE 29 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2023-2030 (USD THOUSAND)

FIGURE 30 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, CAGR (2023-2030)

FIGURE 31 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, LIFELINE CURVE

FIGURE 32 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2022

FIGURE 33 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2023-2030 (USD THOUSAND)

FIGURE 34 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, CAGR (2023-2030)

FIGURE 35 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2022

FIGURE 37 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2023-2030 (USD THOUSAND)

FIGURE 38 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, CAGR (2023-2030)

FIGURE 39 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, LIFELINE CURVE

FIGURE 40 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2022

FIGURE 41 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2023-2030 (USD THOUSAND)

FIGURE 42 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, CAGR (2023-2030)

FIGURE 43 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, LIFELINE CURVE

FIGURE 44 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY END USER, 2022

FIGURE 45 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 46 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, CAGR (2023-2030)

FIGURE 47 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, LIFELINE CURVE

FIGURE 48 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 49 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 50 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 51 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: SNAPSHOT (2022)

FIGURE 53 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022)

FIGURE 54 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 55 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 56 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS (2023-2030)

FIGURE 57 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY SHARE 2022 (%)

View Infographics

FIGURE 1 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 10 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2030

FIGURE 13 THE TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN 2022 & 2030

FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET

FIGURE 16 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023

FIGURE 17 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023-2030 (USD THOUSAND)

FIGURE 18 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, CAGR (2023-2030)

FIGURE 19 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 20 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023

FIGURE 21 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023-2030 (USD THOUSAND)

FIGURE 22 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 23 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, LIFELINE CURVE

FIGURE 24 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023

FIGURE 25 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 26 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 27 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2022

FIGURE 29 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2023-2030 (USD THOUSAND)

FIGURE 30 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, CAGR (2023-2030)

FIGURE 31 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, LIFELINE CURVE

FIGURE 32 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2022

FIGURE 33 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2023-2030 (USD THOUSAND)

FIGURE 34 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, CAGR (2023-2030)

FIGURE 35 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2022

FIGURE 37 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2023-2030 (USD THOUSAND)

FIGURE 38 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, CAGR (2023-2030)

FIGURE 39 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, LIFELINE CURVE

FIGURE 40 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2022

FIGURE 41 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2023-2030 (USD THOUSAND)

FIGURE 42 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, CAGR (2023-2030)

FIGURE 43 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, LIFELINE CURVE

FIGURE 44 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY END USER, 2022

FIGURE 45 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 46 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, CAGR (2023-2030)

FIGURE 47 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, LIFELINE CURVE

FIGURE 48 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 49 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 50 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 51 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: SNAPSHOT (2022)

FIGURE 53 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022)

FIGURE 54 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 55 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 56 NORTH AMERICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS (2023-2030)

FIGURE 57 NORTH AMERICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY SHARE 2022 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19